Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

BACKGROUND Combination long-acting bronchodilator therapy may be more effective than long-acting bronchodilator monotherapy in chronic obstructive pulmonary disease (COPD). OBJECTIVES To compare the efficacy and safety of once-daily umeclidinium/vilanterol (UMEC/VI) 125/25 mcg with placebo and UMEC or VI monotherapy in COPD. METHODS This was a double-blind, placebo-controlled, parallel-group study. A total of 1493 patients were randomized (3:3:3:2) to 24 weeks of treatment with UMEC/VI 125/25 mcg, UMEC 125 mcg, VI 25 mcg, or placebo once-daily via dry powder inhaler. RESULTS Primary efficacy endpoint was trough forced expiratory volume in one second (FEV1) on Day 169 (23-24 h post-dose). Additional lung-function, symptomatic and health-related quality of life endpoints were also assessed. Safety evaluations included: adverse events, vital signs, electrocardiography and clinical laboratory measurements. All active treatments significantly improved trough FEV1 vs placebo (0.124-0.238 L, all p<0.001). Improvements with UMEC/VI 125/25 mcg were significantly greater than for UMEC 125 mcg or VI 25 mcg (0.079 L and 0.114 L; both p≤0.001). Improvements for UMEC/VI 125/25 mcg vs placebo were observed for the transition dyspnea index (1.0 unit; p<0.001), rescue albuterol use at Weeks 1-24 (-1.5 puffs/day) and St. George's Respiratory Questionnaire (-3.60 units, p<0.001). No safety signals were observed. CONCLUSIONS Once-daily UMEC/VI 125/25 mcg was well tolerated and provided greater improvements in lung function, health status, and dyspnea scores compared with monotherapy components and placebo over 24 weeks. This study supports the use of UMEC/VI 125/25 mcg for the maintenance treatment of COPD. CLINICAL TRIAL REGISTRATION protocol number: DB2113361; ClinicalTrials.gov identifier: NCT01313637.

[1]  G. Feldman,et al.  28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. , 2012, Pulmonary pharmacology & therapeutics.

[2]  I. Wiklund,et al.  Development of the Shortness of Breath with Daily Activities questionnaire (SOBDA). , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  E. Bertin,et al.  The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study , 2012, BMC Pulmonary Medicine.

[4]  C. Crim,et al.  The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. , 2012, Chest.

[5]  A. Anzueto,et al.  A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. , 2012, Respiratory medicine.

[6]  G. Feldman,et al.  Safety And Tolerability Of The GSK573719/Vilanterol Combination In Patients With COPD , 2012, ATS 2012.

[7]  E. Bateman,et al.  Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison , 2012, Thorax.

[8]  E. Bateman,et al.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study , 2012, European Respiratory Journal.

[9]  M. Cazzola,et al.  Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[10]  S. Salpeter.  Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events? , 2009, Drugs.

[11]  E. Kerwin,et al.  Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. , 2011, Clinical therapeutics.

[12]  C. Reisner,et al.  Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD , 2011 .

[13]  A. Swensen,et al.  Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. , 2011, Respiratory medicine.

[14]  J. V. van Noord,et al.  QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease , 2010, Thorax.

[15]  M. Decramer,et al.  Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. , 2010, Respiratory medicine.

[16]  M. Cazzola,et al.  The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. , 2010, Pulmonary pharmacology & therapeutics.

[17]  J. Lötvall,et al.  Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. , 2010, American journal of respiratory and critical care medicine.

[18]  C. Jenkins,et al.  Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study , 2009, Respiratory research.

[19]  D. Tashkin,et al.  Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD , 2009, COPD.

[20]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[21]  M. Decramer,et al.  Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.

[22]  J. Bourbeau,et al.  Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.

[23]  V. Brusasco.  Reducing cholinergic constriction: the major reversible mechanism in COPD , 2006, European Respiratory Review.

[24]  J. V. van Noord,et al.  Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. , 2006, Chest.

[25]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[26]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[27]  P. Barnes.  The role of anticholinergics in chronic obstructive pulmonary disease. , 2004, The American journal of medicine.

[28]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[29]  N. Anthonisen,et al.  Hospitalizations and mortality in the Lung Health Study. , 2002, American journal of respiratory and critical care medicine.

[30]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[31]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[32]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.